The ANK3 gene, which encodes ankyrin-G (AnkG), is associated with a variety of neuropsychiatric and cognitive disorders including bipolar disorder, autism spectrum disorder, and schizophrenia. These diseases are characterized by abnormal dendritic and synaptic architecture. AnkG is a multifunctional scaffold protein with several isoforms: The 480 kDa and 270 kDa isoforms have roles at the axon initial segment and node of Ranvier, but the function of the 190 kDa isoform (AnkG-190) is less well understood. Moreover, AnkG isoforms are regulated by palmitoylation, but palmitoylation of AnkG-190 has not been investigated in neurons. Here we show that AnkG is required for normal dendrite and spine architecture in vivo and that stabilizes pyramidal neuron dendrites. We found that palmitoylation at Cys70 stabilizes in spine heads and at dendritic plasma membrane nanodomains. Finally, we found that lithium, a commonly used mood stabilizer, reduces AnkG-190 palmitoylation and increases its mobility in spines by inhibiting ZDHHC8 action. Taken together, our data reveal a novel mechanism regulating dendritic architecture and mood stabilizer action on palmitoylation of an important psychiatric disorder risk factor.
Introduction
The human ANK3 gene, encoding ankyrin-G (AnkG), has been associated with various neuropsychiatric diseases, including bipolar disorder (BD), schizophrenia, and autism spectrum disorder (ASD) (1) (2) (3) . Multiple independent genome wide association studies (GWAS) have strongly linked ANK3 to BD in a variety of different ethnicities (4-7) and have been corroborated by meta-analyses (8) . In addition to a genetic association with ANK3, some studies have shown an increase of ANK3 expression in blood (9) and in lymphoblastoid cells of BD patients (10) , revealing a potential disease mechanism. Furthermore, a BD-related risk variant in ANK3 was associated with decreased expression of a specific AnkG isoform in the cerebellum (11) and variants linked to loss of function are also implicated in ASD and ID (12) . Thus, either increases or decreases of ANK3 gene expression and isoform specific variation may be implicated in disease.
The ANK3 gene encodes multiple isoforms of AnkG, of which the 190, 270, and 480 kDa isoforms are the most prominent in brain (13) . The giant 270 and 480 kDa isoforms have been mostly studied for their function in the axon initial segment (AIS) (14) or in nodes of Ravier (15) , but the 480 kDa isoform has also been shown to prevent gamma-aminobutyric acid (GABA) receptor endocytosis and to have an important role in maintaining GABAergic synapses (16) . The role of the 190 kDa isoform (AnkG-190) is less fully described in neurons, but it can be found in human postsynaptic density (PSD) fraction, where it decreases in BD (17) . Moreover, was found to increase in rat PSD after 5 weeks of lithium treatment (18) . AnkG-190 seems to play an important role in dendritic spine maintenance and long-term potentiation through subsynaptic nanodomains in dendritic spine heads and necks (19) . Given its role in dendritic spines and that BD and schizophrenia are highly correlated to a decreases of dendritic spines and dendrites (20) (21), we reasoned that AnkG-190 may regulate dendrite architecture. However, its function in dendrites has not yet been studied and the regulation of its localization in dendrites and synapses, are not known.
A critical process in the stabilization of proteins in dendritic spines and dendrites is Spalmitoylation, a reversible form of post-translational modification regulating protein attachment to lipid membranes (22) and localizing proteins to different neuronal subcompartments (23) . Important synaptic proteins, including neurotransmitter receptors, scaffold proteins, transporters, adhesion molecules, SNAREs, and other trafficking proteins, are palmitoylated (24) and palmitoylation also regulates dendrite and synapse morphology (25) . However, little is known about the role of palmitoylation in dendrite stability and how it is altered by therapeutic agents.
The membrane-binding regions of all three main AnkG isoforms harbor a cysteine residue (C70) that can be palmitoylated, a process that is required for AnkG association with the membrane, appropriate cellular localization, and function in non-neuronal cells (26, 27) . Structural analysis has shown that the membrane anchoring of AnkG is facilitated by palmitoylation, defining a stable binding interface on the lipid membrane (28) . Interestingly, non-palmitoylated AnkG also localized near the membrane but lacked a unique binding interface. Palmitoylation is known to play an important role in the function of 270 and 480 kDa isoforms, but the role of palmitoylation of the 190 kDa isoform in neurons is unknown (16, 26) .
Lithium is a mood stabilizer commonly used to treat BD patients as a first-line intervention (29) . It has been show than lithium can regulate localization of proteins at the synapse (30) .
Responsiveness of BD patients to lithium treatment appears to be a heritable trait (31) linked to genetic markers in patients isolated from GWAS (32) . The identification of single nucleotide polymorphisms within the ANK3 regulatory region associated to lithium response suggest that AnkG may be involved in lithium-dependent pathways (33) but a little is known about the effect of lithium on the protein's localization and function. Because understanding of synaptic palmitoylation is likely to provide insights into normal neuronal function but also pathophysiological and therapeutic mechanisms (34), we investigated the physiological function of AnkG palmitoylation and its roles in the actions of lithium. We show that AnkG-190 stabilizes pyramidal neuronal basal dendrites and that Palmitoylation stabilizes AnkG-190 in spines and at dendritic plasma membrane nanodomains. Finally, lithium reduces AnkG-190 palmitoylation and increases its mobility in spines in a ZDHHC8-dependent-pathway. Taken together, our data reveal a new role for AnkG-190 in dendritic architecture and a novel mechanism of lithium action on AnkG-190 palmitoylation.
Results
AnkG-190 maintains dendrite complexity in pyramidal neurons. We have previously shown that AnkG-190 has an essential role in dendritic spine maintenance in vitro (19) , but whether AnkG is similarly important in vivo has not been addressed. To investigate this question, we To specifically determine whether the effects in dendrites were cell-autonomous, we knocked down AnkG expression in rat primary cortical neurons using an Ank3 RNAi we previously described (19) . By separating apical and basal dendrites (see supplementary methods), we again found reduced complexity in the basal dendritic arbor of AnkG knockdown pyramidal neurons RNAi-resistant 270 kDa isoform did not ( Fig. 1K ), reminiscent of our previous observations in spines (19) . Notably, AnkG knockdown also reduces dendrite complexity of interneurons, but this effect is only partially rescued by the overexpression of AnkG-270, and cannot be rescued by AnkG-190, suggesting isoform-specific requirements for different neuronal subtypes (SI Appendix, Fig. S1A, B ). Together, these data indicate that the AnkG-190 isoform may have a specific role in maintaining basal dendrite complexity of cortical pyramidal neurons in addition to maintaining spine morphogenesis (19) .
Palmitoylation of C70 stabilizes AnkG-190 in dendritic spine head and dendritic
nanodomains. The specific role of AnkG-190 in dendritic spine and dendrite maintenance led us to ask what post-translational modifications would regulate these specific functions of AnkG-190. Because palmitoylation is a general mechanism for regulation of synaptic proteins, and palmitoylation of AnkG-190 in non-neuronal cells was shown to be essential for the association of AnkG with plasma membranes (26-28), we hypothesized that this modification may also modulate AnkG-190's regulation in dendrites. We first validated the presence of palmitoylated AnkG-190 in rat cortex utilizing the acyl-biotinyl exchange assay (see supplementary methods) (26) , which exchanges palmitoyl modifications with biotin ( Fig. 2A ). We therefore mutated the palmitoylated residue (26) to alanine (C70A) in a GFP fusion construct (GFP-AnkG-190-C70A) to assess how palmitoylation-deficient AnkG-190 would localize in neuronal dendrites and spines ( Fig. 2B ).
Confocal images revealed that overexpressed GFP-AnkG-190 is enriched in the spine head, as previously observed (19) , and this enrichment is lost when C70A was mutated, matching the levels of soluble GFP ( Fig. 2C and D) . To access localization on AnkG-190-C70A of dendritic spines, we used super-resolution structured illumination microscopy (SIM) imaging (19, 36) .
Dendritic spine imaging confirm the confocal data. AnkG-190-C70A seems to prevent formation of nanodomains present in the spine head observed in the AnkG-190 condition ( Fig. 2E ). SIM imaging of dendrites showed that the C70A point mutation did not alter the presence of AnkG-190 at the membrane, but changed its localization pattern ( Fig. 2F ). We found that AnkG-190-C70A has a more diffuse distribution pattern compared to AnkG-190 ( Fig. 2F and G) measured by a smaller variation in fluorescence intensity (Puncta index), suggesting palmitoylation is important to maintain nanodomains along the dendrite.
Lithium reduces AnkG-190 palmitoylation and increases its mobility. Lithium treatment has
been shown to alter the localization of proteins in neurons (30), therefore we reasoned that it may have an effect on palmitoylation, a key post-translational mechanism to affecting subcellular localization. To investigate lithium-dependent modifications of AnkG, we performed an ABE assay in cortical neuron cultures followed by western blotting of AnkG. Interestingly, treatment with lithium resulted in a ~58% decrease in palmitoylated AnkG-190 ( Fig. 3A, B ) which reach levels similar to the control condition containing the palmitoylation inhibitor 2-Bromopalmitate. Interestingly, lithium was not able to reduce GRIP1 palmitoylation (SI Appendix, Fig S3A and B) , another protein present in dendritic spines. Consistent with a reduction in palmitoylation, immunocytochemistry of cortical neuron cultures after lithium treatment revealed a decrease in endogenous AnkG staining in mature spines (width ≥0.8 µm), which contain higher levels of AnkG (19) , compared to vehicle treatment ( Fig. 3C, D) . These data demonstrate that lithium reduces the amount of AnkG localized in spines, which is consistent with the localization of palmitoylationdeficient AnkG. This result led us to hypothesize that lithium could prevent palmitoylation of AnkG-190 and therefore increase AnkG mobility in spines. To test this hypothesis, we performed fluorescence recovery after photobleaching (FRAP) in neurons overexpressing AnkG-190 and treated with lithium for 24 h (Fig. 3E-G) . Interestingly, lithium treatment increased the mobile fraction of AnkG-190 from ~52% to ~75% (Fig. 3G ). This level is comparable to the AnkG-190-C70A which cannot be palmitoylated, and supports an effect of lithium on the reduction of AnkG-190 palmitoylation leading to an increase of its mobility.
Lithium prevents DHHC8 to stabilize AnkG-190 in dendritic spines. Next, we investigated which palmitoyl acyl transferases (PATs) could regulate AnkG-190 mobility in the spine. PATs which have the capability of palmitoylating AnkG have been described in HEK293 and MDCK cells and include ZDHHC5 and ZDHHC8 that target the C70 residue on AnkG-190 (27) . By using overexpression and FRAP imaging in neuron cultures, we verified if ZDHHC5 and ZDHHC8 were able to stabilize AnkG-190 in dendritic spines and if lithium was capable of reversing the process.
To ensure that the effects of palmitoylation were specifically measured, we treated cultures with Palmostatin B, an inhibitor of thioesterase APT1 and APT2 (37), blocking the depalmitoylation pathway. We found that ZDHHC5 did not affect the recovery of fluorescence of GFP-AnkG-190 ( Fig. 4A -C) demonstrating that it does not modulate AnkG-190 mobility in spines. In contrast, ZDHHC8 significantly decreased the GFP-AnkG-190 mobile fraction in the dendritic spine (Fig.   4A , D and E), suggesting it can palmitoylate AnkG-190 and stabilize the protein in the dendritic spine. Moreover, we found that lithium treatment can inhibit the effects of ZDHHC8 overexpression on GFP-AnkG-190 confirming its action on the palmitoylation process.
Discussion
In this study, we demonstrate a role for AnkG-190 in the arborization of pyramidal neuronal dendrites and dendritic spine density in vivo. Multiple Ank3 KO mouse models have severe behavioral deficits related to psychiatric disorders (35, 38) . Our data support that those phenotypes may, at least in part, depend on alterations of dendrite and spine architecture.
Interestingly, reduced dendritic length and spine density have already been described in BD patient brain tissue in post-mortem studies (20) and in iPSCs (21) . Together these observations suggest that altered neuronal morphology has an central role in neuropsychiatric diseases (39) .We identify the AnkG-190 isoform as being specifically required for the cell-autonomous maintenance of basal dendrite arborization in pyramidal neurons, as the 270 kDa form is unable to rescue arborization deficits caused by knockdown of all AnkG isoforms. This phenotype can be due the specific localization of isoforms since AnkG-190 is enriched in dendrites whereas AnkG-270 is enriched in axon (19) . We show that AnkG palmitoylation has a dendritic subcompartmentsspecific role, as it affects only basal but not apical dendrites. This may have implications for pathogenesis of ANK3-deficit-related disorders and bipolar disorder, as basal dendrites receive different inputs, integrate distinct signals, and are selectively regulated in physiological, as compared to apical ones (20, 40) . In addition, loss of AnkG also affects interneuron dendrites, but this dependence relies on other AnkG isoforms, indicating the cell-type specificity of AnkG-190.
We show here that AnkG-190 is palmitoylated in brain tissue, and that this modification is important for AnkG-190 subcellular localization to dendrites and spines. We don't lose AnkG-190 localization at the membrane or in the dendritic spine neck suggesting AnkG-190 can be stabilize by some protein partner interactions like spectrin (19) . However, nanodomains in spine head and dendrites seem to disappear with a diffuse staining along the dendrite membrane.
Unpalmitoylated AnkG has a higher mobility within spines, indicating that palmitoylation restricts its mobility to specific sites, but still conserve a smaller stable population. These data suggest that only a subset of AnkG is palmitoylated at Cystein 70 and other subpopulations of AnkG-190 exist in spines with distinct roles.
Lithium is commonly used for the treatment of mood disorders and may therefore regulate proteins genetically linked to pathophysiology such as ANK3. Analysis of functional SNPs from GWAS data suggest that AnkG may be involved in the lithium response (33) . Lithium has been shown to rescue some BD-related behavioral deficits in different Ank3 KO mouse model (35, 41, 42 ), suggesting it can alleviate symptoms of mouse models with AnkG loss of function. However, heterozygous and homozygous loss of ANK3 likely represent rare mutations only present in a small subset of patients with ASD and ID, and the majority of individuals with BD are likely to retain AnkG expression or have increased expression (9, 10, 43) . Moreover, KO of exon 37 targeting 270 kDa and 480 kDa isoform induce a fivefold expression increase of AnkG-190 isoform (44) . Therefore AnkG-dependent mechanisms may also play a role in the lithium response Only ZDHHC8, one of the two PATs described to palmitoylate AnkG-190 (26), can stabilize GFP-AnkG-190 in dendritic spine when we overexpressed it. This effect is abolish after 24 hour lithium stimulation supporting the decrease of AnkG-190 palmitoylation is due to the inhibition of ZDHHC8 activity. Moreover, palmitoylated GRIP1, which is a target of ZDDHC8 too (26) , is not decrease during lithium treatment indicating a specific inhibition of AnkG-190 palmitoylation.
In summary, we present evidence for a novel mechanism of dendritic architecture controlled by the AnkG-190 isoform. Our work describes a new mechanism of mood stabilizer action and its effects on an important psychiatric disorder risk factor ANK3. These findings open new directions for understanding basic control of neuroarchitecture, but may also provide new opportunities for treatment.
Materials and Methods
Detailed materials and methods can be found in SI Appendix, SI Materials and Methods. Acetone precipitation was performed to remove unreacted HPDP-biotin and hydroxylamine and pellets were resuspended in lysis buffer without MMTS. SDS was diluted to 0.1% (wt/vol) and biotinylated proteins in the samples were affinity-purified using neutravidin-conjugated beads.
Conditional

Beta-mercaptoethanol [1% (vol/vol)] was used to cleave HPDP-biotin and release purified
proteins from the beads. The released proteins in the supernatant were denatured in SDS sample buffer and processed for SDS-PAGE. Adult rat forebrain was dissected, rapidly cooled in ice-cold recording buffer (26) and homogenized in 10 volumes of 4 mM HEPES, 320 mM sucrose, pH 7.4, containing fresh PIC and 20 mM MMTS. Samples were centrifuged to remove debris, brought to room temperature, and SDS was added to 1% (v/v) final concentration. Samples were then centrifuged at 27,000 x g for 30 min at 4°C and supernatants subjected to acetone precipitation and ABE as described above.
Fluorescence recovery after photobleaching: Neurons were imaged at 37°C, 5% CO2, with a Nikon C2 confocal microscope using a 63x oil immersion objective with NA = 1.4 in an OKOLAB stage-type CO2 incubator. Single plane images were captured with an EMCCD camera every 10 s for 200 s. 80% laser power pulses of 1 ms (2 iterations) were used to bleach GFP in the spine.
After background subtraction and validation of maximum 10% remaining fluorescence after photobleaching, data were normalized with the prebleach value. Recovery data points were then fitted to a one-phase association exponential in GraphPad Prism. The mobile fraction was calculated as an average of the plateaued fluorescence level and expressed as a percentage of the pre-bleached level. 
